{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.5","upperLimit":"21.2","value":"8.9"},{"groupId":"OG001","lowerLimit":"12.6","upperLimit":"38.8","value":"23.9"},{"groupId":"OG002","lowerLimit":"4.6","upperLimit":"24.8","value":"12.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"46"},{"groupId":"OG002","value":"49"}],"units":"Participants"}],"description":"Participants achieved an objective response if they had a best overall response of partial response (PR) or complete response (CR). According to RECIST v1.1, PR was defined as at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph node), taking as reference the baseline sum diameter; CR was the disappearance of all non-nodal target lesions, with the short axes of any target lymph node reduced to \\<10 mm, the disappearance of all nontarget lesions, and the normalization of tumor marker levels \\[if tumor markers were initially above the upper limit of normal (ULN)\\]. The percentage of participants who achieved an objective response=(number of participants with CR or PR)/(number of participants assessed)\\*100.","dispersionType":"95% Confidence Interval","groups":[{"description":"Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.\n\nDocetaxel: Docetaxel: 75 mg/m2 on Day 1 of each 21-day cycle","id":"OG000","title":"Docetaxel"},{"description":"Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.\n\nDocetaxel: 75 mg/m2 on Day 1 of each 21-day cycle\n\nRamucirumab (DP): 10 mg/kg IV on day 1 of each 21-day cycle","id":"OG001","title":"Docetaxel + Ramucirumab DP"},{"description":"Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.\n\nDocetaxel: 75 mg/m2 on Day 1 of each 21-day cycle\n\nIcrucumab: 12 mg/kg IV on day 1 and Day 8 of each 21-day cycle","id":"OG002","title":"Docetaxel + Icrucumab"}],"paramType":"NUMBER","populationDescription":"All randomized participants who received one dose of study drug.","reportingStatus":"POSTED","timeFrame":"Randomization to Measured PD (Up to 40 Months)","title":"Percentage of Participants Achieving Objective Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}